Clinical Trial Search

Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)

Primary: Change in Dopamine Transporter Imaging — 4.6; -15.9 % change in arbitrary intensity units

Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale

Primary: Change in MDS-UPDRS Part III Motor (OFF) Score — 0.44; -2.96 score on scale — p=>0.05

Primary: Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12 — -4; -5.9 Score on scale — p=0.0103

Primary: Distribution Volume Ratio — 2.65; 2.70; 2.96; 2.74 Distribution volume ratios — p=0.05

Primary: Tapping Speed Task - Experiment 1 — 110.52; 128.89; 138.43; 145.86 taps/min

Primary: Number of Participants With Serious Adverse Events — 0; 0; 0 Participants

Primary: Change in The International Parkinson and Movement Disorder Society Non-Motor Rating Scale (MDS-NMS) Total Score — -21.2; -18.3 score on a scale

Primary: Sensory Organization Test - Composite Score — 7.7; 0.6 score on a scale

Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468

Primary: Reaction Time and Variability for Movement Task — 1013.858333; 994.94875; 979.2450877; 910.9120833 milliseconds

Primary: Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15 — 0.3; 0.7 Units on a scale — p=0.6503

Primary: Change in Systolic Blood Pressure From Supine to Tilt at 3 Minutes — -24.22; -20.32 mmHg

Primary: Change in Gait Capacity as Assessed b 6-Minute Walk Test — 235.7; 150.0 Feet

Primary: Change in 18F-DTBZ Uptake in a Cohort of Parkinson's Disease Patients From Baseline to Month 36 — 12.95 SUVR

Primary: Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated — 403; 323; 73; 15 Participants

Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753

Primary: AChE PET Neuroimaging — 0.0238; 0.0226 1/min — p=0.0009

Primary: Assessment of the Effectiveness of Two Months of Use of the Remedee Endorphin Band Medical Device in Improving Motor Disorders in Patients With Parkinson's Disease — 6…

Primary: Change in Gait Speed- Sham_On — -0.0185 meters per second (m/s)

Primary: Correlation Coefficient Between UPDRS III Score and Independent Components Analysis Network Strength in Left Parietal Cortex. — 0.5869 unitless

Primary: Change in Magnetoencephalography (MEG) Connectivity Measures

Primary: Change From Baseline in Mean "Off" Time — -0.9; -0.9; -0.8; -0.8 Hours/day — p=0.8700

Primary: Sensitivity of mPDia for the Diagnosis of Neurodegenerative Parkinsonism — 94.30 percentage

Primary: TST — 5.7; 6.0 hours

Primary: Change in Movement of Center of Mass (COM) After Postural Perturbation — 0.31; 0.28; 0.32; 0.26 meters

Primary: Longitudinal Change of Brain Network Activity — 0.41; 0.61; 2.21; 3.61 Z-score in PDRP — p=0.84

Primary: Changes That the Doctor Made in the Clinical Management of Subjects Based Upon the Impact of the Imaging Product. — 33; 28; 19; 11 Number of changes in clinical management

Primary: Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia — 0.97; 2.72 hours — p=0.0083